Waldenstrom Macroglobulinemia - Pipeline Review, H2 2016

  • ID: 3946459
  • Drug Pipelines
  • 199 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • AbbVie Inc
  • arGEN-X BV
  • BeiGene, Ltd.
  • Genentech, Inc.
  • IGF Oncology, LLC.
  • Juno Therapeutics Inc.
  • MORE
Waldenstrom Macroglobulinemia - Pipeline Review, H2 2016

Summary

Our latest Pharmaceutical and Healthcare disease pipeline guide Waldenstrom Macroglobulinemia - Pipeline Review, H2 2016, provides an overview of the Waldenstrom Macroglobulinemia (Oncology) pipeline landscape.

Waldenstrom macroglobulinemia (WM) is a type of non-Hodgkin lymphoma (NHL) that produces large amounts of an abnormal protein (called a macroglobulin). Risk factors include age, gender, family history, Hepatitis C and certain types of autoimmune disease, such as Sjogren syndrome, might be at higher risk for WM. Treatment includes stem cell transplantation, biological therapy, chemotherapy and radiation therapy.

Report Highlights

Our Pharmaceutical and Healthcare latest pipeline guide Waldenstrom Macroglobulinemia - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Waldenstrom Macroglobulinemia (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Waldenstrom Macroglobulinemia (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Waldenstrom Macroglobulinemia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed and Preclinical stages are 2, 16, 10, 1 and 3 respectively for Waldenstrom Macroglobulinemia.

Waldenstrom Macroglobulinemia (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Waldenstrom Macroglobulinemia (Oncology).
- The pipeline guide reviews pipeline therapeutics for Waldenstrom Macroglobulinemia (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Waldenstrom Macroglobulinemia (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Waldenstrom Macroglobulinemia (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Waldenstrom Macroglobulinemia (Oncology)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Waldenstrom Macroglobulinemia (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Waldenstrom Macroglobulinemia (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • AbbVie Inc
  • arGEN-X BV
  • BeiGene, Ltd.
  • Genentech, Inc.
  • IGF Oncology, LLC.
  • Juno Therapeutics Inc.
  • MORE
List of Tables

List of Figures

Introduction

Report Coverage

Waldenstrom Macroglobulinemia Overview

Therapeutics Development

Pipeline Products for Waldenstrom Macroglobulinemia - Overview

Waldenstrom Macroglobulinemia - Therapeutics under Development by Companies

Waldenstrom Macroglobulinemia - Pipeline Products Glance

Late Stage Products

Clinical Stage Products

Early Stage Products

Waldenstrom Macroglobulinemia - Products under Development by Companies

Waldenstrom Macroglobulinemia - Companies Involved in Therapeutics Development

AbbVie Inc

Amgen Inc.

arGEN-X BV

Aurigene Discovery Technologies Limited

Bayer AG

BeiGene, Ltd.

Calithera Biosciences, Inc.

Celgene Corporation

Genentech, Inc.

Gilead Sciences, Inc.

Hutchison MediPharma Limited

IGF Oncology, LLC.

Incyte Corporation

Juno Therapeutics Inc.

Karyopharm Therapeutics, Inc.

Merck KGaA

Millennium Pharmaceuticals Inc

Novartis AG

Ono Pharmaceutical Co., Ltd.

Portola Pharmaceuticals, Inc.

Takeda Pharmaceutical Company Limited

Vivolux AB

Waldenstrom Macroglobulinemia - Therapeutics Assessment

Assessment by Monotherapy Products

Assessment by Combination Products

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Drug Profiles

(dezapelisib + itacitinib adipate) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

765IGF-MTX - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

acalabrutinib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

alisertib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ARGX-110 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BGB-3111 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

bortezomib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CA-4948 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

carfilzomib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CB-839 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

cerdulatinib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

copanlisib hydrochloride - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

dezapelisib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DI-B4 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DTRMWXHS-12 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

entospletinib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

everolimus - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HMPL-523 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

INCB-50465 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

itacitinib adipate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ixazomib citrate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

JCAR-015 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

lenalidomide - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

M-7583 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ONO-4059 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

oprozomib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

selinexor - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit IRAK4 for Immunology and Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

spebrutinib besylate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TAK-659 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

venetoclax - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VLX-1570 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Waldenstrom Macroglobulinemia - Dormant Projects

Waldenstrom Macroglobulinemia - Discontinued Products

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Waldenstrom Macroglobulinemia, H2 2016

Number of Products under Development by Companies, H2 2016

Comparative Analysis by Late Stage Development, H2 2016

Comparative Analysis by Clinical Stage Development, H2 2016

Comparative Analysis by Early Stage Development, H2 2016

Products under Development by Companies, H2 2016

Products under Development by Companies, H2 2016 (Contd..1)

Waldenstrom Macroglobulinemia - Pipeline by AbbVie Inc, H2 2016

Waldenstrom Macroglobulinemia - Pipeline by Amgen Inc., H2 2016

Waldenstrom Macroglobulinemia - Pipeline by arGEN-X BV, H2 2016

Waldenstrom Macroglobulinemia - Pipeline by Aurigene Discovery Technologies Limited, H2 2016

Waldenstrom Macroglobulinemia - Pipeline by Bayer AG, H2 2016

Waldenstrom Macroglobulinemia - Pipeline by BeiGene, Ltd., H2 2016

Waldenstrom Macroglobulinemia - Pipeline by Calithera Biosciences, Inc., H2 2016

Waldenstrom Macroglobulinemia - Pipeline by Celgene Corporation, H2 2016

Waldenstrom Macroglobulinemia - Pipeline by Genentech, Inc., H2 2016

Waldenstrom Macroglobulinemia - Pipeline by Gilead Sciences, Inc., H2 2016

Waldenstrom Macroglobulinemia - Pipeline by Hutchison MediPharma Limited, H2 2016

Waldenstrom Macroglobulinemia - Pipeline by IGF Oncology, LLC., H2 2016

Waldenstrom Macroglobulinemia - Pipeline by Incyte Corporation, H2 2016

Waldenstrom Macroglobulinemia - Pipeline by Juno Therapeutics Inc., H2 2016

Waldenstrom Macroglobulinemia - Pipeline by Karyopharm Therapeutics, Inc., H2 2016

Waldenstrom Macroglobulinemia - Pipeline by Merck KGaA, H2 2016

Waldenstrom Macroglobulinemia - Pipeline by Millennium Pharmaceuticals Inc, H2 2016

Waldenstrom Macroglobulinemia - Pipeline by Novartis AG, H2 2016

Waldenstrom Macroglobulinemia - Pipeline by Ono Pharmaceutical Co., Ltd., H2 2016

Waldenstrom Macroglobulinemia - Pipeline by Portola Pharmaceuticals, Inc., H2 2016

Waldenstrom Macroglobulinemia - Pipeline by Takeda Pharmaceutical Company Limited, H2 2016

Waldenstrom Macroglobulinemia - Pipeline by Vivolux AB, H2 2016

Assessment by Monotherapy Products, H2 2016

Assessment by Combination Products, H2 2016

Number of Products by Stage and Target, H2 2016

Number of Products by Stage and Mechanism of Action, H2 2016

Number of Products by Stage and Route of Administration, H2 2016

Number of Products by Stage and Molecule Type, H2 2016

Waldenstrom Macroglobulinemia - Dormant Projects, H2 2016

Waldenstrom Macroglobulinemia - Discontinued Products, H2 2016

List of Figures

Number of Products under Development for Waldenstrom Macroglobulinemia, H2 2016

Number of Products under Development by Companies, H2 2016

Comparative Analysis by Clinical Stage Development, H2 2016

Comparative Analysis by Early Stage Products, H2 2016

Assessment by Monotherapy Products, H2 2016

Number of Products by Top 10 Targets, H2 2016

Number of Products by Stage and Top 10 Targets, H2 2016

Number of Products by Top 10 Mechanism of Actions, H2 2016

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016

Number of Products by Routes of Administration, H2 2016

Number of Products by Stage and Routes of Administration, H2 2016

Number of Products by Molecule Types, H2 2016

Number of Products by Stage and Molecule Types, H2 2016
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
AbbVie Inc
Amgen Inc.
arGEN-X BV
Aurigene Discovery Technologies Limited
Bayer AG
BeiGene, Ltd.
Calithera Biosciences, Inc.
Celgene Corporation
Genentech, Inc.
Gilead Sciences, Inc.
Hutchison MediPharma Limited
IGF Oncology, LLC.
Incyte Corporation
Juno Therapeutics Inc.
Karyopharm Therapeutics, Inc.
Merck KGaA
Millennium Pharmaceuticals Inc
Novartis AG
Ono Pharmaceutical Co., Ltd.
Portola Pharmaceuticals, Inc.
Takeda Pharmaceutical Company Limited
Vivolux AB
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll